Physician profile
Aman Bali
NPI 1407479413
$2,364.69
in general payments reported to CMS, 2019-2025
14 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2024: $565 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.98 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.06 | 2024-2025 | |
| Janssen Biotech, INC. | $371.07 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $291.11 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.20 | 2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $181.61 | 2024-2025 | |
| Medtronic, INC. | $179.71 | 2022 | |
| Madrigal Pharmaceuticals | $175.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $120.55 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $112.49 | 2025 | Tremfya |
| Ardelyx, INC. | $110.31 | 2024-2025 | Ibsrela |
| Erbe USA INC | $52.99 | 2025 | Vio3 |
| Boston Scientific Corporation | $49.61 | 2025 | Overstitch Endoscopic Suturing System, Orise |
| Genzyme Corporation | $24.21 | 2024 | |
| Novo Nordisk INC | $18.43 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Bali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.